Monoclonaux contre inhibiteurs de tyrosine kinase
作者： A. Bozec , G. Milano
DOI: 10.1007/978-2-287-36008-4_6
关键词:
摘要: Les therapeutiques ciblees en cancerologie font actuellement principalement appel a deux grandes categories de molecules, les anticorps monoclonaux (Mabs) et inhibiteurs tyrosine kinase (TKIs) (1). Dans ce domaine, le ciblage du recepteur au facteur croissance epidermique (REGF) represente, parmi avancees recentes, une des plus prometteuses sur plan clinique (2, 3, 4, 5, 6). Ceci n’a rien ďetonnant quand on connait role cle, tenu par REGF, dans processus transduction signal regulant fonctions cellulaires majeures telles que la survie proliferation. Parmi produits ciblant cetuximab (Erbitux®) (7, 8) panitumumab (Vectibix®) pour Mabs, gefitinib (Iressa®) (9, 10) ľerlotinib (Tarceva®) (11, 12) TKIs, partie agents mieux connus avances leur developpement clinique. Il devient ainsi indispensable comprendre points communs differences concernant proprietes pharmacologiques ces molecules. Si certains elements sont parfaitement connus, nombreuses questions subsistent autour mode ďaction consequences REGF agents. Notre but ici est donc comparer, tant moleculaire clinique, ľaction pharmacologique Mabs TKIs domaine REGF.
springer.com
sci-hub.st 参考文章(120)
John Mendelsohn, Targeting the epidermal growth factor receptor for cancer therapy. Journal of Clinical Oncology. ,vol. 20, ,(2002)
José Baselga, Targeting the epidermal growth factor receptor: a clinical reality. Journal of Clinical Oncology. ,vol. 19, ,(2001)
Sarah B. Noonberg, Christopher C. Benz, Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. ,vol. 59, pp. 753- 767 ,(2000) , 10.2165/00003495-200059040-00003
A. M. Mauer, E. E. W. Cohen, S. J. Wong, M. Kozloff, J. Winegarden, D. M. Gustin, E. E. Vokes, Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) Journal of Clinical Oncology. ,vol. 22, pp. 5539- 5539 ,(2004) , 10.1200/JCO.2004.22.90140.5539
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
Moscatello Dk, Wong Aj, Wong My, McDanel H, Montgomery Rb, Sundareshan P, Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. ,vol. 13, pp. 85- 96 ,(1996)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Paul Carter, Improving the efficacy of antibody-based cancer therapies Nature Reviews Cancer. ,vol. 1, pp. 118- 129 ,(2001) , 10.1038/35101072
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)